CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM042521
035-os BibID:PMID:22124575
Első szerző:Reginster, J-Y.
Cím:Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis / Reginster, J-Y., Kaufman, J-M., Goemaere, S., Devogelaer, J. P., Benhamou, C. L., Felsenberg, D., Diaz-Curiel, M., Brandi, M-L., Badurski, J., Wark, J., Balogh, A., Bruyère, O., Roux, C.
Dátum:2012
ISSN:0937-941X
Megjegyzések:In an open-label extension study, BMD increased continuously with strontium ranelate over 10 years in osteoporotic women (P < 0.01). Vertebral and nonvertebral fracture incidence was lower between 5 and 10 years than in a matched placebo group over 5 years (P < 0.05). Strontium ranelate's antifracture efficacy appears to be maintained long term.INTRODUCTION:Strontium ranelate has proven efficacy against vertebral and nonvertebral fractures, including hip, over 5 years in postmenopausal osteoporosis. We explored long-term efficacy and safety of strontium ranelate over 10 years.METHODS:Postmenopausal osteoporotic women participating in the double-blind, placebo-controlled phase 3 studies SOTI and TROPOS to 5 years were invited to enter a 5-year open-label extension, during which they received strontium ranelate 2 g/day (n = 237, 10-year population). Bone mineral density (BMD) and fracture incidence were recorded, and FRAX? scores were calculated. The effect of strontium ranelate on fracture incidence was evaluated by comparison with a FRAX?-matched placebo group identified in the TROPOS placebo arm.RESULTS:The patients in the 10-year population had baseline characteristics comparable to those of the total SOTI/TROPOS population. Over 10 years, lumbar BMD increased continuously and significantly (P < 0.01 versus previous year) with 34.5 ? 20.2% relative change from baseline to 10 years. The incidence of vertebral and nonvertebral fracture with strontium ranelate in the 10-year population in years 6 to 10 was comparable to the incidence between years 0 and 5, but was significantly lower than the incidence observed in the FRAX?-matched placebo group over 5 years (P?<?0.05); relative risk reductions for vertebral and nonvertebral fractures were 35% and 38%, respectively. Strontium ranelate was safe and well tolerated over 10 years.CONCLUSIONS:Long-term treatment with strontium ranelate is associated with sustained increases in BMD over 10 years, with a good safety profile. Our results also support the maintenance of antifracture efficacy over 10 years with strontium ranelate.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Osteoporosis International 23 : 3 (2012), p. 1115-1122. -
További szerzők:Kaufman, J-M. Goemaere, Stefan Devogelaer, Jean-Pierre Benhamou, C. L. Felsenberg, Dieter Diaz-Curiel, M. Brandi, M-L. Badurski, Janusz E. Wark, J. Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos) Bruyère, Olivier Roux, Christian
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM042526
035-os BibID:PMID: 17997711
Első szerző:Seeman, Ego
Cím:Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia / Seeman Ego, Devogelaer Jean-Pierre, Lorenc Roman, Spector Timothy, Brixen Kim, Balogh Adam, Stucki Gerold, Reginster Jean-Yves
Dátum:2008
ISSN:0884-0431
Megjegyzések:Many fractures occur in women with moderate fracture risk caused by osteopenia. Strontium ranelate was studied in 1431 postmenopausal women with osteopenia. Vertebral fracture risk reduction of 41-59% was shown depending on the site and fracture status at baseline. This is the first report of antivertebral fracture efficacy in women with vertebral osteopenia.INTRODUCTION:Women with osteoporosis are at high risk for fracture. However, more than one half of all fractures in the community originate from the larger population at more moderate risk of fracture caused by osteopenia. Despite this, evidence for antifracture efficacy in these persons is limited. The aim of this study was to determine whether strontium ranelate, a new drug that reduces fracture risk in women with osteoporosis, is also effective in women with osteopenia.MATERIALS AND METHODS:Data from the Spinal Osteoporosis Therapeutic Intervention study (SOTI; n = 1649) and the TReatment Of Peripheral OSteoporosis (TROPOS; n = 5091) were pooled to evaluate the antivertebral fracture efficacy of strontium ranelate in women with lumbar spine (LS) osteopenia with any BMD value at the femoral neck (FN; N = 1166) and in 265 women with osteopenia at both sites (intention-to-treat analysis). The women were randomized to strontium ranelate 2 g/d orally or placebo for 3 yr.RESULTS:No group differences were present in baseline characteristics that may influence fracture outcome independent of therapy. In women with LS osteopenia, treatment reduced the risk of vertebral fracture by 41% (RR = 0.59; 95% CI, 0.43-0.82), by 59% (RR = 0.41; 95% CI, 0.17-0.99) in the 447 patients with no prevalent fractures, and by 38% (RR = 0.62; 95% CI, 0.44-0.88) in the 719 patients with prevalent fractures. In women with osteopenia at both sites, treatment reduced the risk of fracture by 52% (RR = 0.48; 95% CI, 0.24-0.96).CONCLUSIONS:Strontium ranelate safely reduces the risk of vertebral fractures in women with osteopenia with or without a prevalent fracture.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
osteopenia
vertebral fracture risk reduction
strontium ranelate
Megjelenés:Journal of Bone And Mineral Research. - 23 : 3 (2008), p. 433-438. -
További szerzők:Devogelaer, Jean-Pierre Lorenc, Roman Spector, Timothy Brixen, Kim Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos) Stucki, Gerold Reginster, Jean-Yves
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1